TickerHumSide-by-side comparison
Bristol-Myers Squibb vs Johnson & Johnson
As of Nov 11, 2026, P/E is 13.8x for Bristol-Myers Squibb vs 42.3x for Johnson & Johnson; P/S is 2.5x for Bristol-Myers Squibb vs 6.7x for Johnson & Johnson; revenue growth is 4.2% for Bristol-Myers Squibb vs 7.8% for Johnson & Johnson; net margin is 18.5% for Bristol-Myers Squibb vs 16.2% for Johnson & Johnson.
What stands out
- Bristol-Myers Squibb is cheaper on earnings: 13.8x P/E vs 42.3x for Johnson & Johnson.
- Johnson & Johnson carries less debt relative to equity: 0.44 vs 1.79 for Bristol-Myers Squibb.
- Johnson & Johnson's shares did better over the past year: +43.2% vs +27.0% for Bristol-Myers Squibb.
Key metrics
| Metric | BMY | JNJ |
|---|---|---|
| Price | $62.32 | $278.45 |
| Market cap | $127.39B | $670.32B |
| P/E | 13.8x (#1) | 42.3x (#2) |
| P/S | 2.5x (#1) | 6.7x (#2) |
| Revenue growth | 4.2% (#2) | 7.8% (#1) |
| Operating margin | — | — |
| Net margin | 18.5% (#1) | 16.2% (#2) |
| Debt / equity | 1.79 (#2) | 0.44 (#1) |
| 1-year return | +27.0% (#2) | +43.2% (#1) |
| Research score | 69/100 (#1) | 60/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Bristol-Myers Squibb Company (BMY) — Drug Manufacturers—General
- Johnson & Johnson (JNJ) — Drug Manufacturers—General